Kyowa Hakko Kirin Co., Limited

Mitsubishi Denki Kabushiki Kaisha

National Institute of Information and Communications Technology, Incorporated

Osaka University

Nihon Kohden Corporation

Ando Electric Company

Oki Electric Industry Co., Ltd.

Honda Access Corporation

Kabushiki Kaisha Sega

Kabushiki Kaisha Fujikoshi

Japan Oxygen, Co., Ltd.

Nissan Motor Sales Co., Ltd.

Spchange, Llc.

Mitsubishi Electric Corporation

Mitsubishi Electric Home Appliance Co., Ltd.

Hiroshi Ando

Akiko Furuya

Kazuyasu Nakamura

Kenya Shitara

Tsuguo Kubota

Kazuhiro Masuda

Shingo Miyamoto

Ryo Iwamoto

Kumiko Takahashi

Dong Wook Kim

Katsuyoshi Suzuki

Takafumi Suzuki

Hayato Yoshino

Yuka Sasaki

Eisuke Mekada

Masayo Suzuki

Mariko Nakano

Masayuki Hirata

Kaoru Imajo

Eiji Ishikawa

Norihiko Shiraishi

Naoya Kameyama

Munetoshi Ando

Seiji Kameda

Hiroe Toki

Nobukazu Takeuchi

Hiroshi Gokan

Yoshio Takagi

So Ohta

Shigeki Yamakawa

Junichi Tanino

Kunikazu Koura

Masahiro Noda

Akihiro Chida

Junichiro Ishikawa

Shunsuke Yoshida

Koshiro Takano

Satoko Oishi

Tsutomu Katsuyama

Takatsugu Kamata

Akihito Fujiwara

Shougo Tatsumi

Kunio Katou

Toshio Fujimori

Seiichi Akizuki

Shinobu Kawamoto

Takeshi Matsuhashi

Shiro Takehara

Takumi Kobayashi

Yasutaka Gomyo

Akira Ito

Tetsurou Miwa

Toshiyuki Ishisaka

Sumio Yano

Katsutoshi Yamaguchi

Satoshi Hosokawa

Yuji Tsuchiya

An internal device () is implanted in a living body (). A control section () causes a communication section () to wirelessly transmit data corresponding to electroencephalogram signals of the living body () which are detected through a group of N (N is 2 or more) electrodes, to an external device (). When the communication section () receives a designation signal designating a group of M electrode(s) (), M being smaller than N, the communication section () is caused to transmit data corresponding to electroencephalogram signals of the living body () which are detected through the group of M electrode(s) (), to the external device () in real time.

Brain-machine interface system capable of changing amount of communication data from internal device, and control method therefor

An internal device of a brain-machine interface system includes: an electrode group including N electrodes, N being 2 or more; an amplification element group including N amplification elements; a communicator communicating with an external device; and a controller selectively executing one of: a normal operation mode in which electroencephalogram signals acquired through the N electrodes are supplied to the amplification element group in a manner that each of the N electrodes corresponds to a respective one of the N amplification elements, and N amplified electroencephalogram signals are transmitted; and a noise-reduction operation mode in which an electroencephalogram signal acquired through an M electrode of the electrode group is supplied to the amplification element group in a manner that each M electrode corresponds to respective plural ones of the amplification elements, and an M amplified electroencephalogram signal is transmitted, M being smaller than N.

Internal device of brain-machine interface system including noise reduction technique, and method of controlling the internal device

An olfactory display includes a housing and a plurality of fragrance chambers formed in the housing. In each fragrance chamber, a solid-like fragrance source is accommodated and an airflow source is provided to send air into the fragrance chamber from an air intake port. An auxiliary airflow source that emits odorless air is also provided in the housing. The airflow source and the auxiliary airflow source are operated alternately or simultaneously. In response to a user operating an adjustment knob of a controller, operating time periods and stopping time periods of the airflow source and the auxiliary airflow source are changed, or the number of operating times is changed within a predetermined operating time period. A mixing ratio of the fragrance and the odorless air may also be adjusted by changing a voltage value of an alternating voltage to be applied to a piezoelectric device of the airflow source.

Olfactory display

The present invention provides an anti-human FOLR1 antibody against diseases associated with human FOLR1-expressing cells, which specifically recognizes and binds to an amino acid sequence of human FOLR1 or a conformational structure thereof and also has a high effector activity such as antibody-dependent cellular cytotoxicity activity (ADCC activity). The present invention can provide a monoclonal antibody which specifically recognizes and binds to the amino acid sequence of human FOLR1 or the conformational structure thereof and also has ADCC activity and CDC activity, or an antibody fragment thereof, a DNA encoding the antibody, a vector comprising the DNA, a transformant obtained by introducing the vector, a method for producing the antibody or the antibody fragment thereof using the transformant, and a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment as an active ingredient.

Anti-FOLR1 antibody

A side support cover for application to a vehicle seat having a backrest part is disclosed. The side support cover includes left and right cover bodies for covering respective left and right side supports, and left and right lace members with one ends attached to the respective cover bodies. The left and right lace members are connected to the left and right cover bodies at a point positioned in the vicinity of boundaries between the lace members and the side supports. The backrest part has through-holes extending through the backrest part in a front-back direction. The lace members are passed through the respective through-holes in a state of being tensioned.

Side support cover

An olfactory displayincludes a display main bodyand a fragrance source cartridge, and presents a fragrance to a range bounded in terms of time and space. A cartridge accommodation room () of the display main bodyand a container main body () of the fragrance source cartridgeare formed with inclined surfacesandinclined with respect to an insertion direction of the fragrance source cartridge, and a force that pushes in the fragrance source cartridgeacts in a direction that an open air inletis pressed to an air supply portside. Accordingly, adhesiveness of a coupling portion of the air supply portand the open air inletincreases, and therefore, capability of an airflow sourceis used to the utmost, and a high static pressure is generated in the fragrance source cartridgefor a short time.

Olfactory display and fragrance source cartridge used therein

[Structure] An olfactory displayincludes a housinghaving an emitting port, and presents a fragrance within a range bounded in terms of time and space. Within the housing, a fragrance chamberhaving an air inletand a fragrance outletwhich is communicated with the emitting portis formed, and in the fragrance chamber, a solid-like fragrance sourceis accommodated. Furthermore, in the fragrance chamber, there is provided with a airflow sourcecomprising a diaphragmhaving a piezoelectric device. In presenting a fragrance, an air is sent into the fragrance chamberfrom the air inletby the airflow source, and accordingly, the air within the fragrance chamber, which including a gas-like fragrance component volatilized from the fragrance sourceis emitted from the emitting portpassing through the fragrance outlet

An object of the present invention is to provide a monoclonal antibody which is useful for treating or diagnosing a disease relating to system ASC amino acid transporter 2 (hereinafter, referred to as 'ASCT2') or a method using the antibody. The present invention provides a monoclonal antibody which specifically recognizes a native three-dimensional structure of an extracellular region of ASCT2 and binds to the extracellular region, or an antibody fragment thereof; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof, and a diagnostic agent using the antibody or the antibody fragment thereof.

DNA encoding an anti-system ASC amino acid transporter 2 (ASCT2) antibody

A light ray controller has a circular frustum shape and is fitted in a circular hole of a top board such that its large diameter bottom opening faces upward. The light ray controller transmits a light ray while diffusing the light ray in a ridgeline direction and transmits the light ray straightforward without diffusing the light ray in a circumferential direction. A rotation module is provided under the table. One or more scanning projectors are provided on a circumference around an axis of the light ray controller on the rotation base of the rotation module. One or more scanning projectors are rotated by the rotation module. The controller controls one or more scanning projectors being rotated based on three-dimensional shape data stored in a storage.

Three-dimensional display

Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.

Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor

Anti-system ASC amino acid transporter 2 (ASCT2) antibody

An object of the present invention is to provide a monoclonal antibody which is useful as a diagnostic agent or a therapeutic agent for a disease relating to a polypeptide encoded by Claudin-4 (hereinafter referred to as 'CLDN4') gene or a polypeptide encoded by a Claudin-3 (hereinafter referred to as 'CLDN3') gene, or a method for using the same. Accordingly, the present invention provides a monoclonal antibody or an antibody fragment thereof, which specifically recognizes three-dimensional structure of an extracellular region of CLDN4 and binds to the extracellular region; a monoclonal antibody or an antibody fragment thereof, which specifically recognizes three-dimensional structure of both of extracellular regions of CLDN3 and CLDN4 and binds to the extracellular regions; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which comprises the DNA; a transformant obtained by transforming the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a diagnostic agent or a therapeutic agent for a disease relating to a polypeptide encoded by CLDN4 gene and/or CLDN3 gene using the antibody or the antibody fragment.

Anti-claudin-4 antibody

Growing community of inventors

Tokyo, Japan

Hiroshi Ando